JP2018506975A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018506975A5 JP2018506975A5 JP2017542093A JP2017542093A JP2018506975A5 JP 2018506975 A5 JP2018506975 A5 JP 2018506975A5 JP 2017542093 A JP2017542093 A JP 2017542093A JP 2017542093 A JP2017542093 A JP 2017542093A JP 2018506975 A5 JP2018506975 A5 JP 2018506975A5
- Authority
- JP
- Japan
- Prior art keywords
- nucleic acid
- chimeric protein
- domain
- cell
- caspase
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB201503133A GB201503133D0 (en) | 2015-02-24 | 2015-02-24 | Chimeric protein |
| GB1503133.9 | 2015-02-24 | ||
| PCT/GB2016/050451 WO2016135470A1 (en) | 2015-02-24 | 2016-02-23 | Chimeric protein |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020038667A Division JP2020078359A (ja) | 2015-02-24 | 2020-03-06 | キメラタンパク質 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018506975A JP2018506975A (ja) | 2018-03-15 |
| JP2018506975A5 true JP2018506975A5 (https=) | 2019-02-14 |
| JP6836508B2 JP6836508B2 (ja) | 2021-03-03 |
Family
ID=52822149
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017542093A Active JP6836508B2 (ja) | 2015-02-24 | 2016-02-23 | キメラタンパク質 |
| JP2020038667A Withdrawn JP2020078359A (ja) | 2015-02-24 | 2020-03-06 | キメラタンパク質 |
| JP2022092922A Pending JP2022111273A (ja) | 2015-02-24 | 2022-06-08 | キメラタンパク質 |
| JP2024111258A Pending JP2024133176A (ja) | 2015-02-24 | 2024-07-10 | キメラタンパク質 |
Family Applications After (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020038667A Withdrawn JP2020078359A (ja) | 2015-02-24 | 2020-03-06 | キメラタンパク質 |
| JP2022092922A Pending JP2022111273A (ja) | 2015-02-24 | 2022-06-08 | キメラタンパク質 |
| JP2024111258A Pending JP2024133176A (ja) | 2015-02-24 | 2024-07-10 | キメラタンパク質 |
Country Status (20)
| Country | Link |
|---|---|
| US (3) | US10098911B2 (https=) |
| EP (2) | EP4147696A1 (https=) |
| JP (4) | JP6836508B2 (https=) |
| KR (2) | KR20230156817A (https=) |
| CN (2) | CN107207621B (https=) |
| AU (1) | AU2016225190B2 (https=) |
| CA (1) | CA2973107C (https=) |
| CL (1) | CL2017002134A1 (https=) |
| DK (1) | DK3197453T3 (https=) |
| ES (1) | ES2930623T3 (https=) |
| GB (1) | GB201503133D0 (https=) |
| HU (1) | HUE060267T2 (https=) |
| IL (1) | IL252840B (https=) |
| MX (1) | MX392658B (https=) |
| PL (1) | PL3197453T3 (https=) |
| PT (1) | PT3197453T (https=) |
| RU (1) | RU2746755C2 (https=) |
| SG (1) | SG11201705300VA (https=) |
| WO (1) | WO2016135470A1 (https=) |
| ZA (1) | ZA201704231B (https=) |
Families Citing this family (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201503133D0 (en) * | 2015-02-24 | 2015-04-08 | Ucl Business Plc And Syncona Partners Llp | Chimeric protein |
| US20170166877A1 (en) * | 2015-12-14 | 2017-06-15 | Bellicum Pharmaceuticals, Inc. | Dual controls for therapeutic cell activation or elimination |
| ES3051391T3 (en) | 2016-10-06 | 2025-12-29 | Poseida Therapeutics Inc | Inducible caspases and methods for use |
| CN110191955B (zh) * | 2016-12-13 | 2024-05-31 | 西雅图儿童医院（Dba西雅图儿童研究所） | 在体外和体内对工程化的细胞中表达的化学物质诱导的信号传导复合物进行外源性药物激活的方法 |
| JP2020503390A (ja) | 2017-01-09 | 2020-01-30 | オイシン バイオテクノロジーズ， インコーポレイテッド | 治療用タンパク質の標的細胞特異的な産生のため、および標的細胞に関連する疾患、状態、または障害の治療のための、膜融合性脂質ナノ粒子、ならびにその作製および使用のための方法 |
| GB201709203D0 (en) | 2017-06-09 | 2017-07-26 | Autolus Ltd | Antigen-binding domain |
| US20210130775A1 (en) * | 2017-08-02 | 2021-05-06 | Autolus Limited | Cells expressing a chimeric antigen receptor or engineered tcr and comprising a nucleotide sequence which is selectively expressed |
| CN109593721B (zh) * | 2017-09-30 | 2022-11-01 | 亘喜生物科技（上海）有限公司 | 具有自杀基因开关的靶向人间皮素的工程化免疫细胞 |
| GB201716728D0 (en) | 2017-10-12 | 2017-11-29 | Autolus Ltd | Cell |
| GB201717524D0 (en) | 2017-10-25 | 2017-12-06 | Autolus Ltd | Vectors |
| EP3703689A1 (en) * | 2017-11-01 | 2020-09-09 | Allogene Therapeutics, Inc. | Modified caspase-9 polypeptides and methods of use thereof |
| US12331095B2 (en) | 2018-03-14 | 2025-06-17 | Medigene Immunotherapies Gmbh | Inducible T cell receptors and uses thereof |
| GB201805918D0 (en) | 2018-04-10 | 2018-05-23 | Autolus Ltd | Cell |
| CN112312918A (zh) | 2018-04-18 | 2021-02-02 | 奥依信生物技术公司 | 促融合脂质纳米粒和制备其的方法以及其用于靶细胞特异性产生治疗蛋白和治疗与靶细胞有关的疾病、病况或障碍的用途 |
| WO2019210057A1 (en) | 2018-04-27 | 2019-10-31 | Seattle Children's Hospital (dba Seattle Children's Research Institute) | Rapamycin resistant cells |
| GB201813178D0 (en) | 2018-08-13 | 2018-09-26 | Autolus Ltd | Cell |
| US20220145325A1 (en) | 2019-03-08 | 2022-05-12 | Autolus Limited | Compositions and methods comprising engineered chimeric antigen receptor and modulator of car |
| GB201903237D0 (en) | 2019-03-08 | 2019-04-24 | Autolus Ltd | Method |
| GB201906126D0 (en) | 2019-05-01 | 2019-06-12 | Autolus Ltd | Chimeric protein |
| GB201913258D0 (en) | 2019-09-13 | 2019-10-30 | Autolus Ltd | Antigen-binding domain |
| GB201919019D0 (en) | 2019-12-20 | 2020-02-05 | Autolus Ltd | Antigen-binding domain |
| IT202000018064A1 (it) * | 2020-07-27 | 2022-01-27 | Univ Cattolica Del Sacro Cuore | Sviluppo di una nuova proteasi tobacco etch virus (tev) ingegnerizzata attivabile nel citosol o nel pathway secretorio |
| CN112575035B (zh) * | 2020-12-09 | 2022-11-29 | 贵州医科大学 | 一种诱导细胞凋亡的载体系统 |
| GB202019879D0 (en) | 2020-12-16 | 2021-01-27 | Ucl Business Ltd | Polypeptide |
| EP4267601A1 (en) | 2020-12-23 | 2023-11-01 | Quell Therapeutics Limited | Inducible signalling protein |
| GB202117298D0 (en) | 2021-11-30 | 2022-01-12 | Quell Therapeutics Ltd | Signalling protein |
| GB202209920D0 (en) | 2022-07-06 | 2022-08-17 | Autolus Ltd | Cell |
| WO2024251225A1 (en) * | 2023-06-07 | 2024-12-12 | Nanjing Legend Biotech Co., Ltd. | Rapamycin resistant cells and methods of use thereof |
| EP4727972A1 (en) | 2023-06-14 | 2026-04-22 | Autolus Limited | Treatment of trbc1-positive t cell malignancies |
| GB202312009D0 (en) | 2023-08-04 | 2023-09-20 | Autolus Ltd | Methods and cell compositions |
| GB202403564D0 (en) | 2024-03-12 | 2024-04-24 | Autolus Ltd | Method |
| GB202405382D0 (en) | 2024-04-16 | 2024-05-29 | Ucl Business Ltd | Chimeric antigen receptor |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1996041865A1 (en) * | 1995-06-07 | 1996-12-27 | Ariad Gene Therapeutics, Inc. | Rapamcycin-based regulation of biological events |
| US6187757B1 (en) | 1995-06-07 | 2001-02-13 | Ariad Pharmaceuticals, Inc. | Regulation of biological events using novel compounds |
| DE69637641D1 (de) * | 1995-06-07 | 2008-09-25 | Ariad Gene Therapeutics Inc | Auf rapamycin basierende regulation biologischer vorgänge |
| WO1999050425A2 (en) | 1998-03-30 | 1999-10-07 | Baylor College Of Medicine | Regulated apoptosis using chemically induced dimerization of apoptosis factors |
| US20040040047A1 (en) * | 1998-03-30 | 2004-02-26 | Spencer David M. | Regulated apoptosis using chemically induced dimerization of apoptosis factors |
| US6916917B1 (en) * | 1998-11-17 | 2005-07-12 | California Institute Of Technology | Chimeric pro-caspases and methods of using same |
| AU2003226955A1 (en) | 2002-04-19 | 2003-11-03 | Bioimage A/S | Translocation dependent complementation for drug screening |
| CA2593648A1 (en) * | 2005-01-10 | 2006-07-13 | Research Development Foundation | Targeted chimeric molecules for cancer therapy |
| WO2012177927A1 (en) | 2011-06-21 | 2012-12-27 | Mayo Foundation For Medical Education And Research | Transgenic animals capable of being induced to delete senescent cells |
| KR101495651B1 (ko) * | 2012-09-03 | 2015-03-03 | 한국과학기술원 | 빛에 의해 이합체 형성을 유도하는 융합단백질 및 그의 용도 |
| DK2956175T3 (da) | 2013-02-15 | 2017-11-27 | Univ California | Kimærisk antigenreceptor og fremgangsmåder til anvendelse deraf |
| ES2791598T3 (es) * | 2013-06-05 | 2020-11-05 | Bellicum Pharmaceuticals Inc | Métodos para inducir apoptosis parcial utilizando polipéptidos de caspasa |
| ES2918501T3 (es) * | 2013-12-19 | 2022-07-18 | Novartis Ag | Receptores de antígenos quiméricos de mesotelina humana y usos de los mismos |
| EP3114217A4 (en) | 2014-03-07 | 2017-09-20 | Bellicum Pharmaceuticals, Inc. | Caspase polypeptides having modified activity and uses thereof |
| GB201405845D0 (en) | 2014-04-01 | 2014-05-14 | Ucl Business Plc | Signalling system |
| HK1245827B (en) | 2014-12-15 | 2020-06-19 | Board Of Regents Of The University Of Texas System | Methods for controlled activation or elimination of therapeutic cells |
| EP3234144B1 (en) * | 2014-12-15 | 2020-08-26 | Bellicum Pharmaceuticals, Inc. | Methods for controlled elimination of therapeutic cells |
| GB201503133D0 (en) * | 2015-02-24 | 2015-04-08 | Ucl Business Plc And Syncona Partners Llp | Chimeric protein |
| US20220145325A1 (en) | 2019-03-08 | 2022-05-12 | Autolus Limited | Compositions and methods comprising engineered chimeric antigen receptor and modulator of car |
-
2015
- 2015-02-24 GB GB201503133A patent/GB201503133D0/en not_active Ceased
-
2016
- 2016-02-23 EP EP22191585.3A patent/EP4147696A1/en active Pending
- 2016-02-23 JP JP2017542093A patent/JP6836508B2/ja active Active
- 2016-02-23 EP EP16707195.0A patent/EP3197453B9/en active Active
- 2016-02-23 AU AU2016225190A patent/AU2016225190B2/en active Active
- 2016-02-23 CN CN201680006920.1A patent/CN107207621B/zh active Active
- 2016-02-23 SG SG11201705300VA patent/SG11201705300VA/en unknown
- 2016-02-23 WO PCT/GB2016/050451 patent/WO2016135470A1/en not_active Ceased
- 2016-02-23 KR KR1020237038544A patent/KR20230156817A/ko active Pending
- 2016-02-23 DK DK16707195.0T patent/DK3197453T3/da active
- 2016-02-23 PL PL16707195.0T patent/PL3197453T3/pl unknown
- 2016-02-23 CA CA2973107A patent/CA2973107C/en active Active
- 2016-02-23 HU HUE16707195A patent/HUE060267T2/hu unknown
- 2016-02-23 PT PT167071950T patent/PT3197453T/pt unknown
- 2016-02-23 US US15/526,097 patent/US10098911B2/en active Active
- 2016-02-23 KR KR1020177025985A patent/KR102601849B1/ko active Active
- 2016-02-23 ES ES16707195T patent/ES2930623T3/es active Active
- 2016-02-23 CN CN202211656921.4A patent/CN116425882A/zh active Pending
- 2016-02-23 MX MX2017007848A patent/MX392658B/es unknown
- 2016-02-23 RU RU2017132293A patent/RU2746755C2/ru active
-
2017
- 2017-06-12 IL IL252840A patent/IL252840B/en active IP Right Grant
- 2017-06-21 ZA ZA2017/04231A patent/ZA201704231B/en unknown
- 2017-08-21 CL CL2017002134A patent/CL2017002134A1/es unknown
-
2018
- 2018-08-27 US US16/113,098 patent/US10478457B2/en active Active
-
2019
- 2019-10-10 US US16/598,652 patent/US11103532B2/en active Active
-
2020
- 2020-03-06 JP JP2020038667A patent/JP2020078359A/ja not_active Withdrawn
-
2022
- 2022-06-08 JP JP2022092922A patent/JP2022111273A/ja active Pending
-
2024
- 2024-07-10 JP JP2024111258A patent/JP2024133176A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018506975A5 (https=) | ||
| RU2017132293A (ru) | Химерный белок | |
| Willcox et al. | Butyrophilin-like 3 directly binds a human Vγ4+ T cell receptor using a modality distinct from clonally-restricted antigen | |
| Li et al. | Autocrine CTHRC1 activates hepatic stellate cells and promotes liver fibrosis by activating TGF-β signaling | |
| Zeng et al. | γδ T cells recognize a microbial encoded B cell antigen to initiate a rapid antigen-specific interleukin-17 response | |
| Braciale et al. | Immunity to viruses | |
| CN105792840B (zh) | 细胞 | |
| EP3126380B1 (en) | Chimeric antigen receptor (car) signalling system | |
| BR112021007626A2 (pt) | Receptores antigênicos quiméricos específicos pa-ra receptor acoplado à proteína g receptor de classe c, grupo 5, membro d (gprc5d) | |
| US20190169260A1 (en) | Human Leukocyte Antigen Restricted Gamma Delta T Cell Receptors and Methods of Use Thereof | |
| De Bousser et al. | T cell engaging immunotherapies, highlighting chimeric antigen receptor (CAR) T cell therapy | |
| BR112020007576A2 (pt) | composições e métodos para degradação de proteína seletiva | |
| Wang et al. | Conservation of nonpeptide antigen recognition by rhesus monkey Vγ2Vδ2 T cells | |
| JP2018517410A5 (https=) | ||
| JP2015518479A5 (https=) | ||
| SG194398A1 (en) | Cross-species-specific psmaxcd3 bispecific single chain antibody | |
| Shirzadian et al. | SynNotch CAR-T cell, when synthetic biology and immunology meet again | |
| CN112154204A (zh) | 基因工程化的细胞及应用 | |
| JP2020530993A5 (https=) | ||
| Hussein et al. | TCR T cells overexpressing c-Jun have better functionality with improved tumor infiltration and persistence in hepatocellular carcinoma | |
| JP2019535292A5 (https=) | ||
| de Moura et al. | Crystal structure of a soluble decoy receptor IL-22BP bound to interleukin-22 | |
| Stein et al. | The paired receptors TIGIT and DNAM-1 as targets for therapeutic antibodies | |
| Chao et al. | Effector T cell responses unleashed by regulatory T cell ablation exacerbate oral squamous cell carcinoma | |
| JP2018512154A5 (https=) |